No coronavirus-related drug shortages yet, says EMA

The European Medicines Agency (EMA) has said that no drug shortages or supply disruptions due to the coronavirus outbreak have been reported, but that a steering group has convened to address the epidemic’s impact on the supply of medicines in the EU.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Bad news for Italy’s EMA relocation challenge

15 July 2022 EU’s top court denies bid that Amsterdam decision was a “misuse of powers” | Complaint said The Netherlands facility wasn’t ready | Milan lost out after random pick from a fish bowl.

Americas

Fortress offers licences after COVID-19 testing patent backlash

19 March 2020 Labrador Diagnostics, a subsidiary of Fortress Investment Group, has offered royalty-free licences to third parties for its patent-protected diagnostics technology, just days after suing US-based health startup BioFire, which is attempting to develop COVID-19 testing kits.

Big Pharma

FDA reveals COVID-19-related drug shortage

2 March 2020 The US Food and Drug Administration has revealed a COVID-19-related shortage of a drug, adding to concerns that the virus has the potential to massively disrupt medical supply chains.

More on this story

Big Pharma

Bad news for Italy’s EMA relocation challenge

Americas

Fortress offers licences after COVID-19 testing patent backlash

Big Pharma

FDA reveals COVID-19-related drug shortage

2 March 2020 The US Food and Drug Administration has revealed a COVID-19-related shortage of a drug, adding to concerns that the virus has the potential to massively disrupt medical supply chains.

More on this story

Big Pharma

Bad news for Italy’s EMA relocation challenge

Americas

Fortress offers licences after COVID-19 testing patent backlash

Big Pharma

FDA reveals COVID-19-related drug shortage

2 March 2020 The US Food and Drug Administration has revealed a COVID-19-related shortage of a drug, adding to concerns that the virus has the potential to massively disrupt medical supply chains.